YANG Dzhun (US),ЯНГ Джун (US),VU Stiven KH. (US),ВУ Стивен Х. (US),KHERMAN Kliff Dzh. (US),ХЕРМАН Клифф Дж. (US)
申请号：
RU2014120216
公开号：
RU0002640934C2
申请日:
2012.10.31
申请国别(地区):
RU
年份:
2018
代理人:
摘要：
FIELD: pharmacology.SUBSTANCE: method of delivery includes: (a) introduction to the subject of liposomes containing a therapeutic agent, isolated from the group consisting of cisplatin, oxaliplatin, carboplatin, gemcitabine, 5-fluorouracil, doxorubicin and taxane； and (b) introduction to the subject of lipid nanoparticles containing non-ionic substance that triggers the release of therapeutic agent from specified liposomes containing a therapeutic agent in the specified non-ionic substance isolated from the group consisting of D-α-tokopherolpolyethyleneglycol-succinate (TPGS), polyoxyethylene 40 stearate, polyethylene glycol p-(1,1,3,3 tetramethylbutyl) phenyl ester, polyoxyethylene-(2)-isooctylphenyl ether, polyoxyethylene-(150)-dinonylphenyl ether, 2,3-dihydroxipropyl ether of dodecanoic acid, polyoxyethylene-(20)-including sorbitan-monolaurate, polyoxyethylene-(20)-sorbitan-monopalmitate, polyoxyethylene-(20)-sorbitan monostearate, polyoxyethylene-(20)-including sorbitan-monooleate. The set for delivery includes: (a) the first composition containing liposome, comprising of a therapeutic agent； and (b) the second composition containing lipidic nanoparticle that includes non-ionic substance that triggers the release of the therapeutic agent from the specified liposome containing the therapeutic agent, where the first and second compositions are stored separately prior to introduction to the subject.EFFECT: increase in the release of the therapeutic agent from therapeutic liposomes through the use of attacking liposomes containing non-ionic substance that triggers the release of the therapeutic agent.23 cl, 12 dwg, 24 tbl, 12 exИзобретение относится к фармацевтической промышленности, а именно к способу доставки терапевтического агента субъекту, а также к набору для доставки терапевтического агента субъекту. Способ доставки включает: (a) введение субъекту липосомы, содержащей терапевтический агент, выбранный из группы, включающей цисплатин, оксалиплатин, карбоплатин,
